Literature DB >> 26706013

Genotype/Phenotype Correlations in Tuberous Sclerosis Complex.

Paolo Curatolo1, Romina Moavero2, Denis Roberto3, Federica Graziola3.   

Abstract

Tuberous sclerosis complex (TSC) is an autosomal dominant disorder characterized by the development of widespread hamartomatous lesions in various organs, including brain, skin, kidneys, heart, and eyes. Central nervous system is almost invariably involved, with up to 85% of patients presenting with epilepsy, and at least half of patients having intellectual disability or other neuropsychiatric disorders including autism spectrum disorder. TSC is caused by the mutation in one of the 2 genes TSC1, at 9q34, and TSC2, at 16p13.3. They respectively encode for hamartin and tuberin, which form an intracellular complex inhibiting the mammalian target of rapamycin. Mammalian target of rapamycin overactivation following the genetic defect determines the cell growth and proliferation responsible for TSC-related lesions, as well as the alterations in neuronal excitability and synaptogenesis leading to epilepsy and neuropsychiatric disorders. A causative mutation for the disorder is identified in about 85% of patients with a clinical diagnosis of TSC. Mosaicism and technology limits likely explain most of the no mutation identified cases. This review confirms that patients with TSC2 mutations considered as a group usually present a more severe phenotype, characterized by higher number of tubers, earlier age at seizure onset and higher prevalence of intellectual disability. However, the clinical phenotype of the disease presents a high variability, thus making the prediction of the phenotype on an individual basis still challenging. The increasing application of new molecular techniques to subjects with TSC has the potential to significantly reduce the rate of patients with no mutation demonstrated and to identify an increasing higher number of mutations. This would hopefully allow a better characterization of higher risk mutations, which might help clinicians to plan individualized surveillance plans. Furthermore, the increasing availability of disease registries to collect clinical and genetics data of patients help to define more valid and clinically oriented genotype or phenotype correlations.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26706013     DOI: 10.1016/j.spen.2015.10.002

Source DB:  PubMed          Journal:  Semin Pediatr Neurol        ISSN: 1071-9091            Impact factor:   1.636


  26 in total

1.  Re: Coexistence of Autism Spectrum Disorders Among Three Children with Tuberous Sclerosis Complex: Case reports and review of literature.

Authors:  Mahmood D Al-Mendalawi
Journal:  Sultan Qaboos Univ Med J       Date:  2017-03-30

2.  [Two novel TSC2 frameshift mutations in tuberous sclerosis complex].

Authors:  Yu-Chun Pan; Wei-Qing Wu; Jian-Sheng Xie; Cai-Qun Luo; Ying Hao
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2017-03

3.  Clinical Characteristics of Connective Tissue Nevi in Tuberous Sclerosis Complex With Special Emphasis on Shagreen Patches.

Authors:  Michelle A Bongiorno; Neera Nathan; Oyetewa Oyerinde; Ji-An Wang; Chyi-Chia Richard Lee; G Thomas Brown; Joel Moss; Thomas N Darling
Journal:  JAMA Dermatol       Date:  2017-07-01       Impact factor: 10.282

4.  Genotype and brain pathology phenotype in children with tuberous sclerosis complex.

Authors:  Iris E Overwater; Rob Swenker; Emma L van der Ende; Kimberley Bm Hanemaayer; Marianne Hoogeveen-Westerveld; Agnies M van Eeghen; Maarten H Lequin; Ans Mw van den Ouweland; Henriëtte A Moll; Mark Nellist; Marie-Claire Y de Wit
Journal:  Eur J Hum Genet       Date:  2016-07-13       Impact factor: 4.246

5.  mTOR Inhibitor Treatment in Patients with Tuberous Sclerosis Complex Is Associated with Specific Changes in microRNA Serum Profile.

Authors:  Bartłomiej Pawlik; Urszula Smyczyńska; Szymon Grabia; Wojciech Fendler; Izabela Dróżdż; Katarzyna Bąbol-Pokora; Katarzyna Kotulska; Sergiusz Jóźwiak; Julita Borkowska; Wojciech Młynarski; Joanna Trelińska
Journal:  J Clin Med       Date:  2022-06-13       Impact factor: 4.964

Review 6.  Thoracoabdominal imaging of tuberous sclerosis.

Authors:  Cara E Morin; Nicholas P Morin; David N Franz; Darcy A Krueger; Andrew T Trout; Alexander J Towbin
Journal:  Pediatr Radiol       Date:  2018-08-04

7.  mTOR Hyperactivity Levels Influence the Severity of Epilepsy and Associated Neuropathology in an Experimental Model of Tuberous Sclerosis Complex and Focal Cortical Dysplasia.

Authors:  Lena H Nguyen; Travorn Mahadeo; Angélique Bordey
Journal:  J Neurosci       Date:  2019-01-30       Impact factor: 6.167

8.  Presentation and Diagnosis of Tuberous Sclerosis Complex in Infants.

Authors:  Peter E Davis; Rajna Filip-Dhima; Georgios Sideridis; Jurriaan M Peters; Kit Sing Au; Hope Northrup; E Martina Bebin; Joyce Y Wu; Darcy Krueger; Mustafa Sahin
Journal:  Pediatrics       Date:  2017-11-03       Impact factor: 7.124

9.  Pattern of TSC1 and TSC2 germline mutations in Russian patients with tuberous sclerosis.

Authors:  Evgeny N Suspitsin; Grigoriy A Yanus; Marina Yu Dorofeeva; Tatiana A Ledashcheva; Nataliya V Nikitina; Galina V Buyanova; Elena V Saifullina; Anna P Sokolenko; Evgeny N Imyanitov
Journal:  J Hum Genet       Date:  2018-02-23       Impact factor: 3.172

10.  Predictive Power of EEG in Infants with Tuberous Sclerosis.

Authors:  Molly Tracy
Journal:  Pediatr Neurol Briefs       Date:  2016-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.